

1 Defining Key Deprescribing Measures from Electronic Health Data: A Multisite Data  
2 Harmonization Project

3

4 Short title: Deprescribing Measures from EHR Data

5

6 Authors: Sascha Dublin, MD, PhD<sup>a,b,c</sup>, Ladia Albertson-Junkans, MPH<sup>a</sup>, Thanh Phuong Pham

7 Nguyen, PharmD, MBA, MSCE<sup>d</sup>, Juliessa M. Pavon, MD, MHS<sup>e,f</sup>, Susan N. Hastings, MD,

8 MHS<sup>e,f,g</sup>, Matthew L. Maciejewski, PhD<sup>e,g,h</sup>, Allison Willis, MD, MS<sup>d</sup>, Lindsay Zepel, MS<sup>h</sup>, Sean

9 Hennessy, PharmD, PhD<sup>d</sup>, Kathleen B. Albers, MPH<sup>i</sup>, Danielle Mowery, PhD, MS<sup>d</sup>, Amy G.

10 Clark, PhD<sup>h</sup>, Sunil Thomas, MBA/TM<sup>d</sup>, Michael A. Steinman, MD<sup>i,k</sup>, Cynthia M. Boyd, MD,

11 MPH<sup>l</sup>, Elizabeth A. Bayliss, MD, MSPH<sup>i,m</sup>

12

13 Author Affiliations:

14 <sup>a</sup>Kaiser Permanente Washington Health Research Institute, Seattle, WA

15 <sup>b</sup>University of Washington Department of Epidemiology, Seattle, WA

16 <sup>c</sup>Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA

17 <sup>d</sup>University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

18 <sup>e</sup>Duke University School of Medicine, Durham, NC

19 <sup>f</sup>Durham VA Healthcare System, Geriatrics Education Research and Clinical Centers

20 <sup>g</sup>Durham VA Center of Innovation to Accelerate Discovery and Practice Transformation

21 <sup>h</sup>Duke University, Department of Population Health Sciences

22 <sup>i</sup>Kaiser Permanente Colorado Institute for Health Research, Aurora, CO

23 <sup>j</sup>Division of Geriatrics, University of California San Francisco, San Francisco, CO

24 <sup>k</sup>San Francisco Veterans Administration Medical Center, San Francisco, CA

25 <sup>l</sup>Division of Geriatric Medicine and Gerontology and Center for Transformative Geriatric

26 Research, Johns Hopkins University School of Medicine, Baltimore, MD

27 <sup>m</sup>Department of Family Medicine, University of Colorado School of Medicine, Aurora, CO

28

29 Corresponding author: Dr. Sascha Dublin, 1730 Minor Avenue, Suite 1600, Seattle, WA, 98101.

30 Email: [Sascha.Dublin@kp.org](mailto:Sascha.Dublin@kp.org).

31

32 Disclosures (all funding sources): This work was funded by National Institute on Aging grants

33 R24AG064025 and 1K23AG058788-03 (Pavon) and US Department of Veterans Affairs grant

34 RCS 10-391 (Maciejewski). The contents do not represent the views of the U.S. Department of

35 Veterans Affairs or the United States Government.

36

37 Prior presentations: Portions of this paper were presented at the US Deprescribing Research

38 Network Annual Meeting in Long Beach, California in May 2023; at the International

39 Conference on Pharmacoepidemiology in Halifax, Nova Scotia in August 2023; and at the

40 National Association of Primary Care Research Group annual meeting in San Francisco,

41 California in November 2023.

42

43 Word count: abstract 300 words, main text 1996 words

44 Tables/figures: 3

45

46 **Impact Statement:**

47 We certify that this work is novel. Prior papers have identified a need for greater standardization  
48 of definitions for medication exposure and discontinuation in deprescribing studies. To our  
49 knowledge, no prior paper has systematically examined the construction of deprescribing  
50 variables from electronic health data. This is the first paper to present standardized definitions  
51 for variables needed for deprescribing studies based on electronic health data, to implement these  
52 definitions in multiple healthcare systems and data types, and to examine their performance. This  
53 is also the first paper to examine the impact of using medication orders vs. dispensing data to  
54 define key deprescribing variables.

55

56 **Key points:**

- 57 • Using benzodiazepines and Z-drugs as a case study, we developed and implemented  
58 standardized definitions for key variables needed for deprescribing studies using  
59 electronic health records data from 5 diverse U.S. healthcare systems.
- 60 • Requiring a gap of  $\geq 90$  days without an active order/dispensing or, for a fixed time point,  
61 requiring a period of  $\geq 30$  days surrounding it with no order/dispensing will likely  
62 increase the accuracy of identifying true medication discontinuation.
- 63 • Applying definitions to medication orders data generated higher estimates of chronic use  
64 and lower estimates of medication discontinuation than dispensing data.

65

66 **Why does this paper matter?** The use of standardized variable definitions in deprescribing  
67 studies will improve the ability to synthesize data and compare results between studies,  
68 advancing knowledge and supporting more evidence-based guidelines for clinical care.

69

70 **Abstract**

71 **Background:** Deprescribing, or systematically stopping or reducing risky or unneeded  
72 medications, could improve older adults' health. Electronic health records (EHR) hold promise  
73 for supporting deprescribing studies, but there are currently no standardized measures for key  
74 variables. With benzodiazepines and other sedative-hypnotics (Z-drugs) as a case study, we  
75 developed and examined EHR-based definitions for chronic medication use and discontinuation.

76 **Methods:** We conducted a retrospective cohort study set within 5 U.S. healthcare systems. The  
77 study population was adults age 65+ from 2017-2019 with chronic benzodiazepine or Z-drug  
78 use, without dementia or serious mental illness. We used EHR data for medication orders and  
79 dispensings to define key variables, including chronic benzodiazepine/Z-drug use and  
80 discontinuation. We explored definitions for discontinuation based on 1) gaps in medication  
81 availability during follow-up (no active order/dispensing) or 2) not having medication available  
82 at a fixed time point. We examined the impact of varying gap length from 30 to 180 days,  
83 accounting for stockpiling, and requiring a 30-day period without orders/dispensings ("halo")  
84 around the fixed time point. We also compared results from medication orders vs. dispensings  
85 for the same population.

86 **Results:** 1.6-2.6% of older adults had chronic use of a benzodiazepine or Z-drug. Depending on  
87 the definition and site, the proportion discontinuing use over 12 months ranged from 6% to 49%.  
88 Requiring a longer gap in orders/dispensings or a 30-day "halo" around a fixed time point  
89 resulted in lower estimates. Orders data were less likely to identify discontinuation than  
90 dispensing data.

91 **Conclusions:** Requiring a medication gap of  $\geq 90$  days or a 30-day period with no  
92 orders/dispensings around a fixed time point may improve the likelihood that an outcome

93 represents true discontinuation. Orders data appear to underestimate discontinuation compared to  
94 dispensing data. More work is needed to adapt and test the proposed definitions for other drug  
95 classes and care settings.

96

97 **Keywords (3-5):** deprescribing, measurement, electronic health records, benzodiazepines,

98 medication discontinuation

99

100

101

## 102 **Introduction**

103 Polypharmacy is common in older adults and has been associated with many adverse  
104 outcomes.[1-4] A potential solution is deprescribing – systematically stopping or tapering  
105 medications that are risky or no longer needed, with ongoing monitoring.[5, 6] There are  
106 important gaps in the evidence about deprescribing, including its impact on health outcomes.

107 Electronic health records (EHR) data can support evidence generation, for instance by  
108 supporting efficient recruitment and outcome ascertainment for randomized controlled trials  
109 (RCTs). They can also be used for observational studies. Benefits include access to large and  
110 more representative populations.

111 Deprescribing studies have used heterogeneous definitions for key outcome variables,  
112 including chronic medication use and discontinuation, hindering comparison and synthesis of  
113 results.[7] EHR-based definitions for these variables have not been systematically proposed or  
114 examined. To address this gap, the US Deprescribing Research Network convened a workgroup  
115 to develop and implement standardized EHR-based definitions for key variables for  
116 deprescribing studies.

## 117 **Methods**

### 118 **Overview**

119 Researchers from 5 U.S. healthcare systems met regularly, selecting high-priority  
120 variables and collaboratively developing definitions that each site operationalized. We carried  
121 out a retrospective cohort study, identifying individuals with chronic medication use and  
122 following them to identify discontinuation. As a case study, we chose benzodiazepines and  
123 related sedative-hypnotics (zolpidem, eszopiclone, and zaleplon, or “Z-drugs”), common targets

124 for deprescribing. To provide a framework, we emulated some elements of D-PRESCRIBE, a  
125 community-based deprescribing RCT.[8]

## 126 **Study settings and data sources**

127 Participating healthcare systems (Appendix Table 1) included 2 integrated healthcare  
128 systems, regions of Kaiser Permanente (KP); two academic healthcare systems, the University of  
129 Pennsylvania and Duke University; and the Durham Veterans Affairs Health Care System  
130 (VAHCS). The first 4 use Epic EHRs. All systems have EHR data for demographic  
131 characteristics, visits, diagnoses, and medication orders. The KP regions also have claims data,  
132 including health plan enrollment and pharmacy dispensings. Medication orders come from the  
133 EHR and show prescriptions ordered by a clinician, while dispensing data are generated by  
134 pharmacies as part of filling these prescriptions. One academic site obtained dispensing data  
135 from a vendor, Surescripts, while the other had only orders data.

## 136 **Study population**

137 Inclusion and exclusion criteria were modeled after D-PRESCRIBE (see Appendix Table  
138 2). We included people aged 65 and older who engaged with our healthcare systems from 2017-  
139 2019. We required chronic use of a benzodiazepine or Z-drug in 2018 (definitions follow). We  
140 excluded people with serious mental illness or significant cognitive impairment and those  
141 needing an interpreter.

## 142 **Defining chronic benzodiazepine or Z-drug use**

143 Table 1 provides definitions for key variables. We also provide a Programmers' Guide  
144 (Supplemental Appendix Text) with practical and technical guidance for implementing the  
145 definitions. Sites with dispensing data defined chronic benzodiazepine/Z-drug use as having  $\geq 3$   
146 dispensings and  $\geq 45$  days' supply within 100 days. The rationale for the days' supply

147 requirement is that a more stringent definition of chronic use will identify individuals at higher  
148 risk of harm and make it easier to ascertain discontinuation accurately. When using orders data to  
149 define chronic use, we required  $\geq 3$  orders within 100 days, counting the initial order and any  
150 refills included. Implicitly, these definitions assume that a typical dispensing/prescription is for  
151  $\leq 30$  days' supply. The orders-based definition does not include a days' supply requirement  
152 because orders generally lack this element. When defining chronic use in 2018, we considered  
153 dispensings/orders from 2017 and 2018.

154 Individuals were assigned an "index date" which separated the baseline period, during  
155 which chronic use was assessed, from the follow-up period, during which discontinuation was  
156 assessed. In dispensing data, the index date was the date of the dispensing that qualified a person  
157 as having chronic use (i.e., the third dispensing or the dispensing that led to  $\geq 45$  total days'  
158 supply). It is challenging to assign an index date from orders data because people may qualify as  
159 having chronic use based on allowed refills, which do not have a set start date. Thus, for people  
160 meeting chronic use criteria in 2018 based on orders, we assigned 1/1/2019 as the index date.

### 161 **Baseline characteristics**

162 We extracted data about demographics, diagnoses, and medication use (Appendix Table  
163 3). We ascertained opioid use because these medications are often used with benzodiazepines,  
164 and concomitant use increases the risk of adverse outcomes. Chronic opioid use was identified  
165 using the same definition as for benzodiazepines/Z-drugs.

166 We measured the number of chronic medications other than benzodiazepines/Z-drugs on  
167 the index date. First, we identified those where the index date fell within the medication's days'  
168 supply (using dispensing data) or on or between an order's start and end date. For dispensings,  
169 we included only those with  $\geq 28$  days' supply. We excluded products that are not chronic



170 medications (e.g., vaccines). We then counted the number of distinct national drug codes for  
171 dispensing data or generic medication names (for orders).

## 172 **Defining medication discontinuation**

173 We took two conceptual approaches (Table 1): 1) determining whether a person had  
174 stopped use for a set *duration of time* at any point during a specified follow-up period (“gap-  
175 based” definition) and 2) determining whether the person had stopped using the medication at a  
176 *fixed time point* during follow-up. We followed individuals for 12 months after the index date.

177 For dispensings, a medication was considered “in use” from the dispensing date through  
178 the run-out date, defined as dispensing date + days’ supply – 1 (assuming the first dose is taken  
179 on the dispensing date). If there was not another dispensing within 30 days after the run-out date,  
180 we considered this a 30-day gap. Similarly, we identified gaps of 60, 90, or 180 days. As a  
181 variation, we defined gaps accounting for medication stockpiling.

182 For orders, a medication was considered “in use” from the order start date through the  
183 end date. The order end date accounts for allowed refills (essentially, assuming all allowed refills  
184 were utilized). It can be retroactively modified by various events, such as the patient reporting  
185 that they stopped the medication.

186 For the fixed time point definition, we assessed whether a person appeared to have the  
187 medication on hand at a given time point (Appendix Figure 1a). If the time point did not fall  
188 within a period when the medication was in use, this was considered discontinuation. We defined  
189 discontinuation at days 90, 180, 270 and 365 of follow-up. We realized that for a person  
190 continuing use, a fixed time point could fall within a brief gap between two dispensings. Thus, as  
191 a variation, we required that the fixed time point fall within a 30-day period with no dispensings  
192 or orders (“halo”; see Appendix Figure 1b).

193 We created variables for discontinuation using the gap-based and fixed time point  
194 approaches and compared the results.

### 195 **Comparing results from medication orders versus dispensings**

196 Orders and dispensing data differ in important ways that could affect measurement.  
197 Orders lack information about days' supply, and it is impossible to determine whether allowed  
198 refills were dispensed or when. The order end date is calculated assuming all refills were used,  
199 potentially overestimating use. We utilized data from KPWA, which has both orders and  
200 dispensing data, to define chronic benzodiazepine/Z-drug use and discontinuation using both  
201 data types for a set population and examined agreement.

### 202 **Results**

203 In 2018, the prevalence of chronic use of benzodiazepines/Z-drugs ranged from 1.5% to  
204 2.6% across sites (Appendix Figure 2). Appendix Figures 3a-3f show the impact of inclusion and  
205 exclusion criteria. People with chronic benzodiazepine/Z-drug use had a mean age of 71.5-73.3  
206 years, about two-thirds were female (except at the VAHCS), and most were white (Appendix  
207 Table 3). Between 31-66% had a diagnosis of anxiety in the EHR and 4-31% a diagnosis of  
208 insomnia.

209 Across sites, the proportion of people with a gap in use of  $\geq 30$  days during follow-up  
210 varied from 13-49% and for gaps  $\geq 180$  days, from 6-15% (Figure 1). As the gap length  
211 increased, the proportion discontinuing decreased. Site 5, which used orders data, had the lowest  
212 apparent discontinuation rates.

213 With the fixed time point definition, the proportion of individuals who discontinued  
214 benzodiazepine/Z-drug use ranged from 9-32% at 180 days after the index date and from 20-36%  
215 at 365 days (Figure 2). Requiring a 30-day "halo" with no order/dispensing around the fixed

216 point led to substantially lower estimates. Discontinuation rates were slightly lower after  
217 adjustment for stockpiling (Appendix Figure 4), but for longer gaps, this adjustment mattered  
218 less.

219 In an analysis of individuals at one site with both orders and dispensing data, far more  
220 people appeared to have chronic benzodiazepine/Z-drug use based on orders than dispensings  
221 (Appendix Table 4a). Of those with chronic use defined from orders, only 56% also qualified  
222 based on dispensings. The discrepancy was greatest among individuals who qualified based on a  
223 single order (Appendix Table 4b). Discontinuation rates derived from dispensings were  
224 substantially higher than from orders (Appendix Table 5); for example, at 180 days after index  
225 date, the discontinuation rate was 32% based on dispensings vs. 20% based on orders.

## 226 **Discussion**

227 We found that at 5 U.S. healthcare systems in 2018, 1.5-2.6% of older adults were using  
228 benzodiazepines or Z-drugs chronically. For comparison, a U.S. study using dispensing data  
229 found that in 2008, 2.7% of people aged 65-80 had long-term benzodiazepine use,[9] while in  
230 Canada in 2006, 3.5% of older adults had long-term use.[10]

231 This multisite investigation yielded three key insights. First, discontinuation rates over 12  
232 months of follow-up ranged from 6 to 49% depending on the definition; requiring a longer gap to  
233 qualify as discontinuation resulted in a lower discontinuation rate. Our results suggest that gaps  
234 of 30 or 60 days may be less likely to represent true discontinuation than longer gaps. Second,  
235 when defining discontinuation at a fixed time point, requiring a 30-day “halo” period resulted in  
236 lower discontinuation rates. This indicates that many people received subsequent orders/fills  
237 shortly after the time point, suggesting they did not truly discontinue. Third, data from orders  
238 classified more people as having chronic use and identified fewer discontinuations than

239 dispensing data. Using orders data for this purpose poses challenges, including ambiguity about  
240 refill usage. Orders may remain active long after use has stopped. Thus, dispensing data are  
241 likely more precise for these purposes.

242 This is the first paper to examine the construction of deprescribing variables from EHR  
243 data systematically. Our results align with some prior findings. Niznik et al. examined  
244 bisphosphonate discontinuation and recommended requiring longer gaps ( $\geq 90$  days).[11]  
245 Another study compared definitions of opioid use from orders vs. dispensing data. They had  
246 orders data from a single healthcare system and found that dispensing data yielded higher opioid  
247 use estimates than orders (the reverse of our findings).[12] These results illustrate the challenges  
248 of using orders data, in this case the potential to underestimate use due to fragmentation of care.

249 Strengths of this project include the involvement of 5 healthcare systems representing  
250 different U.S. regions, patient populations, and types of data. We examined several definitions  
251 for medication discontinuation and developed a programmers' guide (see Appendix).

252 Benzodiazepines and Z-drugs are controlled substances and are the subject of many  
253 policies, guidelines and regulations. Some of these limit prescriptions to 30 days' supply[13],  
254 and at our sites most dispensings were for  $\leq 30$  days. This influenced our algorithms. Other  
255 chronic medications are often prescribed with 90 days' supply, which may affect the  
256 transferability of our definitions. Also, benzodiazepines/Z-drugs are often used sporadically,  
257 making it harder to identify discontinuation compared to daily medications. We lacked a gold  
258 standard against which we could evaluate our definitions' performance. Our study did not  
259 investigate the reasons for discontinuation, so we could not distinguish between clinically  
260 recommended discontinuation and patient-driven discontinuation without clinical support.

261 Additional research is needed to understand the intent behind observed discontinuations  
262 and to develop EHR-based definitions for dose reduction or tapering. Our proposed definitions  
263 should be adapted and tested for other chronic medications and care settings.

264 In conclusion, it is feasible to develop and apply standardized, EHR-based definitions for  
265 deprescribing variables in diverse settings. When selecting variable definitions, researchers  
266 should consider the potential impacts of misclassification given their study design and aims. Our  
267 goal is to provide guidance for these decisions and to support greater standardization of  
268 measures, improving the evidence base for deprescribing.

269

270 **Acknowledgments**

271

272 Conflicts of interest: SD has received funding from GSK. SH has consulted for or received  
273 funding from Pfizer, Johnson & Johnson, Novo Nordisk, Arbor Pharmaceuticals, the Medullary  
274 Thyroid Cancer Consortium (Novo Nordisk, AstraZeneca, GlaxoSmithKline and Eli Lilly),  
275 Biogen, Intercept Pharmaceuticals, Provention Bio, bluebird bio, and Amylyx Pharmaceuticals.  
276 TPPN was a member of the 2022-2023 Junior Investigator Intensive Program of the US  
277 Deprescribing Research Network, which is funded by the National Institute on Aging, and has  
278 received support from Acadia Pharmaceuticals. MM owns stock in Amgen. Other authors have  
279 no conflicts to report.

280

281 **Author Contributions:**

282 Study concept and design: SD, LAJ, TPPN, JMP, SNH, MLM, AGC, SH, AW, KBA, DM, EAB

283 Acquisition of data: LAJ, KBA, DM, LZ, ST

284 Analysis and interpretation of data: all authors

285 Preparation of manuscript: all authors

286

287 Sponsor's Role: The sponsor did not play a role in study design, methods, data collection,  
288 analysis, or preparation of the manuscript.

289

290

291 **References**

- 292 1. Chang, T.I., et al., *Polypharmacy, hospitalization, and mortality risk: a nationwide*  
293 *cohort study*. Sci Rep, 2020. **10**(1): p. 18964.
- 294 2. Laflamme, L., et al., *Type, number or both? A population-based matched case-control*  
295 *study on the risk of fall injuries among older people and number of medications beyond*  
296 *fall-inducing drugs*. PLoS One, 2015. **10**(3): p. e0123390.
- 297 3. Leelakanok, N., et al., *Association between polypharmacy and death: A systematic review*  
298 *and meta-analysis*. J Am Pharm Assoc (2003), 2017. **57**(6): p. 729-738.e10.
- 299 4. Park, H.Y., et al., *The Association between Polypharmacy and Hip Fracture in*  
300 *Osteoporotic Women: A Nested Case-Control Study in South Korea*. Clin Drug Investig,  
301 2019. **39**(1): p. 63-71.
- 302 5. Woodward, M.C., *Deprescribing: Achieving Better Health Outcomes for Older People*  
303 *through Reducing Medications*. J Pharm Pract Res, 2003. **33**: p. 323-8.
- 304 6. Thompson, W. and B. Farrell, *Deprescribing: what is it and what does the evidence tell*  
305 *us?* Can J Hosp Pharm, 2013. **66**(3): p. 201-2.
- 306 7. Bayliss, E.A., et al., *Recommendations for outcome measurement for deprescribing*  
307 *intervention studies*. J Am Geriatr Soc, 2022. **70**(9): p. 2487-2497.
- 308 8. Martin, P., et al., *Effect of a Pharmacist-Led Educational Intervention on Inappropriate*  
309 *Medication Prescriptions in Older Adults: The D-PRESCRIBE Randomized Clinical*  
310 *Trial*. Jama, 2018. **320**(18): p. 1889-1898.
- 311 9. Olfson, M., M. King, and M. Schoenbaum, *Benzodiazepine use in the United States*.  
312 JAMA Psychiatry, 2015. **72**(2): p. 136-42.

- 313 10. Cunningham, C.M., G.E. Hanley, and S. Morgan, *Patterns in the use of benzodiazepines*  
314 *in British Columbia: examining the impact of increasing research and guideline cautions*  
315 *against long-term use*. Health Policy, 2010. **97**(2-3): p. 122-9.
- 316 11. Niznik, J.D., et al., *Patterns of oral bisphosphonate deprescribing in older nursing home*  
317 *residents with dementia*. Osteoporos Int, 2022. **33**(2): p. 379-390.
- 318 12. Young, J.C., et al., *Considerations for observational study design: Comparing the*  
319 *evidence of opioid use between electronic health records and insurance claims*.  
320 *Pharmacoepidemiol Drug Saf*, 2022. **31**(8): p. 913-920.
- 321 13. Tennessee State Government. *New Law Restricts Amount of Some Powerful Drugs That*  
322 *Can be Dispensed in Tennessee*. 2013 October 11, 2013 [cited 2023 September 2].

323

324



325 **Figure Legend**

326

327 Figure 1. Prevalence of medication discontinuation during 12 months of follow-up across sites,  
328 using a gap-based definition and varying gap length.

329

330 Figure 2. Prevalence of medication discontinuation during 12 months of follow-up across sites,  
331 using the fixed time point definition. Estimates for Sites A-D are adjusted for stockpiling. Site E  
332 estimates are based on orders data and given challenges in measuring order end dates, there was  
333 no adjustment for stockpiling.

334

335 **List of Supplemental Material for Online Publication**

336

337 Supplemental Appendix Text: Programmers' Guide. Provides detailed technical and practical  
338 guidance for working with orders and dispensing data to implement the definitions of  
339 deprescribing variables presented in this paper.

340

341 Appendix Table 1: Descriptions of healthcare systems participating in Data Harmonization  
342 Workgroup

343 Appendix Table 2: Definitions of inclusion and exclusion criteria and lists of diagnosis codes and  
344 medications

345 Appendix Table 3: Characteristics of people aged 65 or older with chronic benzodiazepine or Z-  
346 drug use at 5 US healthcare systems

347 Appendix Table 4a: Comparing chronic use defined from medication orders vs. dispensings for  
348 the same population

349 Appendix Table 4b: Comparing chronic use defined from medication orders vs. dispensings,  
350 stratified by number of medication orders

351 Appendix Table 5: Comparing measures of discontinuation defined from orders vs. dispensing  
352 data for the same population

353 Appendix Figure 1a: Illustration of fixed time point definition of discontinuation, without halo

354 Appendix Figure 1b: Illustration of fixed time point definition of discontinuation, with halo. In  
355 the top row, representing no discontinuation, there are dispensings or orders within the 30-day  
356 halo period around the fixed point. In the bottom line, representing discontinuation, there are no  
357 dispensings or orders within the 30-day halo period around the fixed point. Note: the 30-day

358 period does not have to be symmetric around the fixed point; it represents any 30-day period that  
359 contains the fixed point within it.

360 Appendix Figure 2. Prevalence of Benzodiazepine and Z-drug Use in People Aged  $\geq 65$  Within 5  
361 U.S. Healthcare Systems, 2018.

362 Appendix Figures 3a-3f: Results of Applying Inclusion and Exclusion Criteria at Each Site

363 Appendix Figure 4: Impact of Adjusting for Medication Stockpiling on Estimated

364 Discontinuation Rates (Using Gap-Based Definition)

**Table 1: Definitions for Deprescribing Measures\***

| Measure  | Definition  |
|--|---|
| Chronic benzodiazepine/<br>Z-drug use, from dispensing<br>data | ≥3 dispensings and a total of ≥45 days' supply within 100 days.   |
| Chronic benzodiazepine/<br>Z-drug use, from orders data        | ≥3 orders within 100 days, counting both the initial order and any refills included.  |
| Discontinuation:<br>Gap-based measure                          | <p>For dispensing data: during 12 months of follow-up, the presence of a period of X days after the run-out date of a dispensing without a subsequent dispensing. The “run-out date” was defined as the date of dispensing + days' supply -1.</p> <p>For orders data: during 12 months of follow-up, the presence of a period of X days following the end date of an order without a new medication order.</p> <p>In this study we examined gap lengths of 30, 60, 90 and 180 days.</p>   |
| Discontinuation:<br>Fixed time point measure                   | <p>For dispensing data: Discontinuation defined as present if the fixed time point of interest does not fall within a period when the medication was “in use,” that is, within the dispensed days' supply for a dispensing of the medication.</p> <p>For orders data: Discontinuation defined as present if the fixed time point does not fall within a time period when the medication is “in use,” that is, on or between the start and end dates for an order for the medication.</p> <p>Fixed time points considered in this study: 90, 180, 270 and 365 days after index date.</p> <p>As a variation, we explored the impact of also requiring a “halo” of 30 days around the fixed time point with no medication orders or dispensings.</p> |
| Number of chronic<br>medications used at baseline              | Number of medications “in use” on the index date that had at least 28 days' supply, excluding certain products that are not chronic medications (e.g., vaccines, allergenic extracts, toxoids, supplies such as glucose test strips, and others).   |

\*Please see the accompanying Programmers' Guide (Supplemental Appendix Text) for detailed practical and technical guidance about implementing the definitions.



